The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA) vaccine (ARCT-154) for COVID-19 in adults. The approval marks the first milestone for a November 2022 licensing deal under which CSL subsidiary CSL Seqirus in-licensed Arcturus’ late-stage sa-mRNA vaccine platform technology.
Current antiviral agents for COVID-19 treatment target viral proteins, which are susceptible to mutation during SARS-CoV-2 evolution. A potential strategy to fight emerging drug resistances is the development of compounds targeting host proteins that are indispensable for the viral life cycle.
In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA) vaccine (ARCT-154) for COVID-19 in adults. The approval marks the first milestone for a November 2022 licensing deal under which CSL subsidiary CSL Seqirus in-licensed Arcturus’ late-stage sa-mRNA vaccine platform technology.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Arcturus, Arrowhead, Carisma, CSL, Effector, Ethris, Novavax, Orexo, Sernova, Springworks.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Cellcentric, CNS, Entrada, Fluoguide, Index, Ingeneron, Innovent.
Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury.
RSS
